Zhang Y et al. |
Enhanced osteoclastic resorption and responsiveness to mechanical load in gap junction deficient bone. |
2011 |
PLoS ONE |
pmid:21897843
|
Titanji K et al. |
Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection. |
2014 |
PLoS Pathog. |
pmid:25393853
|
Lis GJ et al. |
Influence of osteoclasts and osteoprotegerin on the mode of calcific degeneration of aortic valves. |
2016 |
Pol. Arch. Med. Wewn. |
pmid:27003233
|
Janda K et al. |
Osteoprotegerin as a marker of cardiovascular risk in patients on peritoneal dialysis. |
2013 |
Pol. Arch. Med. Wewn. |
pmid:23535831
|
Nehring P et al. |
Osteoprotegerin gene rs2073617 and rs3134069 polymorphisms in type 2 diabetes patients and sex‑specific rs2073618 polymorphism as a risk factor for diabetic foot. |
2013 |
Pol. Arch. Med. Wewn. |
pmid:23299915
|
Jasiewicz M et al. |
Potential pathogenic role of soluble receptor activator of nuclear factor-ĸB ligand and osteoprotegerin in patients with pulmonary arterial hypertension. |
2014 |
Pol. Arch. Med. Wewn. |
pmid:25188298
|
Stajszczyk M |
[Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism]. |
2002 |
Pol. Arch. Med. Wewn. |
pmid:12600190
|
Adamczyk T et al. |
Biomarkers of calcification and atherosclerosis in patients with degenerative aortic stenosis in relation to concomitant coronary artery disease. |
2012 |
Pol. Arch. Med. Wewn. |
pmid:22237719
|
Ambroszkiewicz J et al. |
[Concentration of osteoprotegerin, bone formation and resorption markers in patients with phenylketonuria]. |
2008 |
Pol. Merkur. Lekarski |
pmid:18839616
|
Kmieć Z and Sokołowska I |
[Role of tumor necrosis factor family ligands in the pathogenesis of rheumatoid arthritis--new therapeutical opportunities]. |
2007 |
Pol. Merkur. Lekarski |
pmid:17684931
|
Hen K et al. |
[Osteoprotegerin--a new atherosclerosis marker]. |
2011 |
Pol. Merkur. Lekarski |
pmid:22097184
|
Ostrowska Z et al. |
Circadian concentrations of free testosterone, selected markers of bone metabolism, osteoprotegerin and its ligand sRANKL in obese postmenopausal women. |
2011 |
Postepy Hig Med Dosw (Online) |
pmid:22100799
|
Ostrowska Z |
[Menopause, obesity, and bone status]. |
2009 |
Postepy Hig Med Dosw (Online) |
pmid:19252463
|
Ostrowska Z et al. |
Assessment of the relationship between melatonin, hormones of the pituitary-ovarian, -thyroid and -adrenocortical axes, and osteoprotegerin and its ligand sRANKL in girls with anorexia nervosa. |
2013 |
Postepy Hig Med Dosw (Online) |
pmid:23752595
|
Zdzisińska B and Kandefer-Szerszeń M |
[The role of RANK/RANKL and OPG in multiple myeloma]. |
2006 |
Postepy Hig Med Dosw (Online) |
pmid:17013366
|
Majerczyk M et al. |
[Osteoprotegerin as a marker of atherosclerosis and a prognostic factor in stroke]. |
2015 |
Postepy Hig Med Dosw (Online) |
pmid:27259222
|
Stanisławowski M and Kmieć Z |
[The participation of RANK, RANKL and OPG in tumor osteolysis]. |
2009 |
Postepy Hig Med Dosw (Online) |
pmid:19502684
|
Ostrowska Z et al. |
 Dehydroepiandrosterone sulfate, osteoprotegerin and its soluble ligand sRANKL and bone metabolism in girls with anorexia nervosa. |
2012 |
Postepy Hig Med Dosw (Online) |
pmid:23001207
|
Wang Y et al. |
Chicken receptor activator of nuclear factor-kappaB ligand induces formation of chicken osteoclasts from bone marrow cells and also directly activates mature osteoclasts. |
2008 |
Poult. Sci. |
pmid:18931186
|
Jiang S et al. |
Changes of blood parameters associated with bone remodeling following experimentally induced fatty liver disorder in laying hens. |
2013 |
Poult. Sci. |
pmid:23687138
|
Fu YX et al. |
Influence of osteoprotegerin on differentiation, activation, and apoptosis of Gaoyou duck embryo osteoclasts in vitro. |
2013 |
Poult. Sci. |
pmid:23687158
|
Ta HM et al. |
Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis. |
2010 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:21059944
|
Yasuda H et al. |
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. |
1998 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:9520411
|
Hsu H et al. |
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. |
1999 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:10097072
|
Shimamura M et al. |
OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in mice. |
2014 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:24847069
|
Xiong L et al. |
Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption. |
2015 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:25733894
|
Duheron V et al. |
Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit. |
2011 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:21402940
|
Chen W et al. |
Arthritogenic alphaviral infection perturbs osteoblast function and triggers pathologic bone loss. |
2014 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:24733914
|
Wei W et al. |
Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. |
2012 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:22315431
|
Krause U et al. |
Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. |
2010 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:20150512
|
Pearse RN et al. |
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. |
2001 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:11562486
|
Raffai RL et al. |
Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. |
2001 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:11553788
|
Toraldo G et al. |
IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. |
2003 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:12490655
|
Li JY et al. |
Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand. |
2011 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:21187391
|
Baud'huin M et al. |
A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength. |
2012 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:22761317
|
Cozzani M et al. |
Transcription Factor Decoy (TFD) as a novel approach for the control of osteoclastic resorption. |
2005 |
Prog Orthod |
pmid:16276433
|
Malik P et al. |
Bone mineral density and bone metabolism in patients with major depressive disorder without somatic comorbidities. |
2013 |
Prog. Neuropsychopharmacol. Biol. Psychiatry |
pmid:23380173
|
Kuroyanagi G et al. |
Suppression by resveratrol of prostaglandin D2-stimulated osteoprotegerin synthesis in osteoblasts. |
2014 |
Prostaglandins Leukot. Essent. Fatty Acids |
pmid:24813642
|
Fujita D et al. |
Prostaglandin E2 induced the differentiation of osteoclasts in mouse osteoblast-depleted bone marrow cells. |
2003 |
Prostaglandins Leukot. Essent. Fatty Acids |
pmid:12711253
|
Poulsen RC et al. |
Long chain polyunsaturated fatty acids alter membrane-bound RANK-L expression and osteoprotegerin secretion by MC3T3-E1 osteoblast-like cells. |
2008 |
Prostaglandins Other Lipid Mediat. |
pmid:18077200
|
Li X et al. |
Prostaglandin receptor EP2 mediates PGE2 stimulated hypercalcemia in mice in vivo. |
2002 |
Prostaglandins Other Lipid Mediat. |
pmid:12013525
|
Kuroyanagi G et al. |
(-)-Epigallocatechin gallate synergistically potentiates prostaglandin E2-stimulated osteoprotegerin synthesis in osteoblasts. |
2017 |
Prostaglandins Other Lipid Mediat. |
pmid:28163121
|
Blackwell KA et al. |
Bone morphogenetic protein 2 enhances PGE(2)-stimulated osteoclast formation in murine bone marrow cultures. |
2009 |
Prostaglandins Other Lipid Mediat. |
pmid:19744575
|
Wiercinska-Drapalo A et al. |
Transforming growth factor beta1 and prostaglandin E2 concentrations are associated with bone formation markers in ulcerative colitis patients. |
2005 |
Prostaglandins Other Lipid Mediat. |
pmid:16303613
|
Yamamoto N et al. |
Resveratrol reduces prostaglandin E1-stimulated osteoprotegerin synthesis in osteoblasts: suppression of stress-activated protein kinase/c-Jun N-terminal kinase. |
|
Prostaglandins Other Lipid Mediat. |
pmid:25677506
|
Armstrong AP et al. |
RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. |
2008 |
Prostate |
pmid:18008334
|
Corey E et al. |
Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. |
2002 |
Prostate |
pmid:11992617
|
Burton DW et al. |
Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. |
2005 |
Prostate |
pmid:15389781
|
Yonou H et al. |
Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts. |
2007 |
Prostate |
pmid:17394194
|
Eaton CL et al. |
Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. |
2004 |
Prostate |
pmid:15042606
|